NewsCura

D&L Industries, Inc.

Disclaimer: The research and recommendation below were generated by Claude Fable. Please treat this as one input for your own research — not as the sole basis for any decision to buy or sell a stock.

Last checked
Price
3.5400
Trading status
Normal
Recommendation
Hold (dividend not cash-covered; BIR tax case pending)Hold
Committee call
Sell
Indices
MidCap

Analysis

DNL - D&L Industries, Inc.

One-line summary: diversified specialty chemicals/food ingredients conglomerate trading at a genuinely de-rated 10x P/E with a real growth runway (Batangas plant, biodiesel, consumer ODM), but the dividend has been funded by rising debt rather than free cash flow for five straight years.

Snapshot
Reviewed July 19, 2026
Index membership PSE MidCap
Price at review P3.54 (July 17, 2026 close)
Recommendation Hold (cheap on paper, but the dividend isn't cash-covered; don't buy or sell yet)
Market cap P25.29B (7.14B shares)
Trailing P/E ~9.82x
Forward P/E (est.) ~9.60x
Dividend (2026) P0.236/share (P0.182 regular + P0.054 special), ~6.0-6.4% yield
P/B ~1.07x
Debt D/E 1.11 (up from 0.74 in 2021)

Core business and revenue trend

D&L is a Lao-family-controlled specialty chemicals and food ingredients conglomerate built on coconut oil as the common feedstock across four segments: Food Ingredients, Specialty Plastics, Oleochemicals/Biodiesel (Chemrez), and Consumer Products ODM (contract manufacturing for personal care and home care brands). Because most contracts pass commodity costs through with a 30-45 day lag, revenue tends to swing with coconut oil prices even when volumes are stable.

Revenue and net income, FY2021-2025: P30.9B / P2.64B (2021), P43.5B / P3.32B (2022, a commodity-price and post-pandemic peak), P33.5B / P2.30B (2023, Batangas plant startup year), P40.7B / P2.34B (2024), P55.4B / P2.59B (2025). The 2025 revenue jump (+36%) outran earnings growth (+11%) because coconut oil prices nearly tripled over two years and get passed through in the topline; the real earnings story runs through the segments, not the headline revenue number.

Q1 2026 shows the pass-through lag working the other way: revenue fell 10% to P12.82B as commodity prices eased, while net income rose 5% to P717M as margins expanded (blended gross margin 13.4%, up 0.7 points). TTM net income (to March 2026) is P2.625B on P53.9B revenue, in line with the FY2025 run rate.

Segment growth drivers

The segments diverge sharply, and that dispersion is the real 2025 story:

  • Consumer Products ODM (the Batangas plant): earnings up 80% in FY2025 and 65% in Q1 2026, on 14% volume growth and margin expansion. The plant is still running below 50% utilization after its sixth straight profitable quarter, so there is real capacity runway left before this becomes a mature, fully-utilized asset.
  • Chemrez (biodiesel/oleochemicals): net income up 96% in FY2025 on a higher mandated biodiesel blend and global coconut-oil-derivative demand.
  • Specialty Plastics: earnings up 9% in FY2025 with margins at record levels.
  • Food Ingredients: earnings down 61% in FY2025, the weakest segment, hit hardest by the coconut oil spike and the pricing lag.

The diversification is doing real work: a commodity-driven segment (Food Ingredients) got hurt badly in 2025 while three other segments carried the group to a net income record. That's a structural advantage over a single-segment name, but it also means headline earnings quality depends on which segments are in or out of favor with input prices in any given year.

Dividend sustainability

The 2026 declaration is P0.182 regular plus a P0.054 special dividend, P0.236 total, ex-date June 22, 2026, record date June 23, 2026, paid July 8, 2026. That is a payout ratio of 65% of FY2025 EPS (P0.363), and it marks the sixth straight year D&L has layered a special dividend on top of the regular one since the pandemic. Yield is roughly 5.9% to 6.6% depending on which price is used.

The payout-vs-earnings math looks fine. The payout-vs-cash math does not: dividends paid have exceeded free cash flow in every one of the last five years. FCF was negative in four of five years (2021: -P3.39B, 2022: -P1.72B, 2024: -P1.04B, 2025: -P0.28B) and even in the one positive year, 2023 (+P1.14B), it still fell short of the P1.71B paid out that year. Dividends paid ran P1.0B-P1.7B annually throughout, meaning the payout has been financed externally (debt or balance sheet draws), not by organic cash generation, for the entire five-year window. Some of that is explained by heavy Batangas-plant capex in 2021-2022 (>P3.5B/year); capex has since eased to under P1B, which could let FCF turn durably positive if operating cash flow keeps improving. It hasn't happened yet.

ROE

ROE has been fairly stable at 11.0%-11.6% for the last three years (11.06% in 2023, 10.98% in 2024, 11.60% in 2025, 11.40% currently), down from a 2021-2022 peak of 14.3%-16.7%. This is a moderate, not spectacular, return on equity for a specialty manufacturer, and it isn't obviously flattered by a thin equity base the way a pure payout story would be, but rising leverage (see below) means a growing share of that return is debt-financed.

Free cash flow

Operating cash flow has been volatile and generally weak relative to net income: P204M (2021), P1.98B (2022), P2.55B (2023), just P4.25M (2024, essentially zero), P568M (2025). Capex has stepped down from the Batangas-build peak of P3.6B-P3.7B (2021-2022) to P1.0B-P1.4B (2023-2024) to P849M (2025). Free cash flow, the difference: -P3.39B, -P1.72B, +P1.14B, -P1.04B, -P0.28B. Only one of the last five years produced positive free cash flow, and even that year didn't cover the dividend. The direction (falling capex, improving Consumer ODM margins) points toward a better FCF picture ahead, but it is a forward hope, not yet a demonstrated fact.

Capital allocation

Capex has been genuinely expansionary (the Batangas plant, a P10B build), not harvesting; it is now tapering as the plant matures. The company keeps paying and growing the dividend (six straight years of special dividends) through a period when organic cash flow didn't support it, funded instead by debt: debt/equity has risen from 0.74 (2021) to 1.11 (current). There is no buyback program; capital return is dividend-only.

On the ownership side, the Lao family controls roughly 72.8% of the company (62.2% through holding company Jadel, 10.4% held directly by family members), with only about 27% free float. Notably, Jadel has been adding to its stake rather than trimming: roughly 106 million shares bought in 2025 and another 4 million in early 2026, a ~4.4% stake increase since the pandemic. Insider buying by the controlling family at a depressed valuation is a genuine positive signal, though the thin float that results also means the stock can be illiquid.

The other overhang worth flagging: a D&L subsidiary, Oleo Fats, Inc. (OFI), was subpoenaed by the Department of Justice in 2025 over a Bureau of Internal Revenue tax evasion complaint alleging "ghost purchases" used to overstate expenses and understate taxable income for 2019-2020. This is a preliminary investigation, not a conviction or even a filed criminal case yet, and the company denies wrongdoing, but it is an unresolved legal risk with an unquantified potential fine or reputational cost.

Verdict at P3.54 (July 19, 2026)

Hold, not a Buy and not a Sell, though the case has softened since the July 12 review. The price drifted down from P3.64 to P3.54 (about -2.7%), and the analyst picture turned more cautious: FY2026 consensus estimates were cut across the board (revenue from P55.7B to P54.9B, EPS from P0.434 to P0.376), and the price-target spread widened to P4.10-P6.60 across just 3 covering analysts, with the low end recently cut from P4.60. Q2 2026 results still aren't due until August 5, and the BIR/OFI tax case remains an unresolved preliminary investigation with no new developments since Aug-Sept 2025. The valuation case is otherwise unchanged: P/E has compressed from 25.5x (2021) to ~9.82x today, and P/B from 3.53x to ~1.07x, while earnings actually grew across most segments, meaning this isn't a peak-earnings mirage the way a cheap-looking cyclical usually is. The Batangas plant still has real headroom (under 50% utilized), biodiesel demand and mandated blending are tailwinds, and the controlling family is buying more stock at this price rather than selling.

Set against that: dividends have been paid out of debt, not free cash flow, in every one of the last five years, and leverage has risen accordingly (D/E 0.74 to 1.11). That is a genuine capital-allocation flag, not a one-off. Layer on a pending BIR tax evasion case against a subsidiary with an unknown financial outcome, a thin 27% public float, downward estimate revisions, and margin swings tied to coconut oil pricing lags, and the cheap multiple looks like fair compensation for real risk rather than a clear mispricing. None of the buy or sell triggers below have fired this week, but the estimate cuts are a small step in the wrong direction, not a trigger on their own.

What would change the call:

  • Buy trigger: free cash flow (OCF minus capex) turns and stays positive for two consecutive years, covering the dividend without new borrowing, or debt/equity stabilizes/declines from 1.11x while earnings keep growing.
  • Buy trigger: the BIR/OFI case is resolved with no material fine or conviction, removing the legal overhang.
  • Sell trigger (if owned): debt/equity keeps climbing past roughly 1.3x-1.5x while FCF stays negative, or the Lao family reverses course and starts selling down its stake, or Food Ingredients-style margin pressure spreads into the currently strong segments (Consumer ODM, Chemrez, Plastics).
  • Sell trigger: a materially adverse ruling or settlement in the BIR case.

Thin free float on PSE small/mid caps can make exits slow. Analysis, not financial advice.

Committee review (July 19, 2026)

Five investor lenses judged this page's facts independently, each confined strictly to its own framework.

Lens Signal Confidence Core argument
Ben Graham Bearish 68 Net income has swung 30%+ year to year (P2.64B to P3.32B to P2.30B) with no clean decade-long stability, and debt/equity climbed from 0.74 to 1.11 while dividends (P1.0-1.7B/year) exceeded free cash flow in four of the last five years, funded partly by borrowing. At P/B 1.07x there is no real margin of safety over net asset backing, and rising leverage against unstable earnings fails the senior-claims test.
Warren Buffett Bearish 78 ROE has slid from 14-16% to ~11% while debt/equity rose from 0.74 to 1.11, the opposite of what Buffett wants. Owner earnings don't support the payout: FCF was negative in four of five years, yet dividends of P1.0-1.7B were paid every year regardless. A commodity-input business with a live tax-evasion investigation into a subsidiary is neither a durable moat nor a clean integrity signal.
Michael Burry Bearish 63 FCF has been negative in four of five years (P-1.04B in 2024, P-0.28B in 2025) while dividends were paid anyway, funded by balance-sheet stretch, not cash generation. Operating cash flow of P4.25M in 2024 against reported net income of P2.34B is exactly the earnings-versus-cash divergence that should trigger scrutiny, with D/E climbing from 0.74 to 1.11 confirming the gap is bridged with leverage.
Nassim Taleb Bearish 64 Dividends have exceeded FCF for five straight years, funded by rising leverage (D/E 0.74 to 1.11) rather than earnings, a classic hidden fragility masked by "steady" payout optics. The unresolved DOJ/BIR tax probe into Oleo Fats is an unbounded, uncompensated tail risk sitting under a modest 11% ROE. Jadel's insider buying is the one real skin-in-the-game counterweight, but it doesn't offset the debt-funded distribution structure.
Stanley Druckenmiller Bearish 62 No live catalyst until Q2 earnings on August 5, and the estimate-revision trend is negative: FY2026 EPS consensus cut from P0.434 to P0.376 and revenue from P55.7B to P54.9B, with the stock already drifting down (P3.64 to P3.54). Payoff is asymmetric to the downside: paying out 65% of earnings above free cash flow for five straight years leaves no cushion if the August print misses the already-lowered bar.

Conferred call: Sell (5 bearish). This disagrees with the page's Hold, and the disagreement widened from last week: Druckenmiller flipped from bullish to bearish now that the fresh downward analyst estimate revisions (EPS P0.434 to P0.376, revenue P55.7B to P54.9B) removed the near-term momentum case, leaving all five lenses aligned against the position for the first time. Checked against the trading rulebook ([[stock-trading-strategy-and-rules]]), the setup still does not clear the bar: cheap valuation and insider buying are present, but there is no confirmed price momentum or chart breakout, and the rulebook explicitly warns against buying purely because a stock looks cheap. The page's Hold (rather than a hard Sell) reflects that the position is a "don't buy, don't force an exit" call for anyone already holding, not a case for fresh buying; a unanimous committee is a reason to watch the position more closely, not necessarily to force an exit before Q2 results. Shared flip trigger: All five lenses converge on the same threshold: sustainably positive free cash flow that covers the dividend without added debt, combined with a clean resolution of the OFI/BIR tax case, would flip the committee decisively bullish. Druckenmiller additionally wants a Q2 earnings beat against the lowered consensus.

Review history

Date Price Recommendation
July 10, 2026 3.60 Hold (cheap on paper, dividend not cash-covered)
July 12, 2026 3.64 Hold (no change; committee's conferred call is Sell)
July 19, 2026 3.54 Hold (no change; analyst estimates cut, committee now unanimously Sell)

Sources